Half-year statement of IPSEN liquidity agreement – 2024 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
PARIS, FRANCE, July 8, 2024 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2024, the following resources were included to the dedicated liquidity account:
- 34,591 shares
- €1,418,034.45
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2024 and June 30, 2024 have been executed:
- 3,232 purchase transactions
- 2,431 sell transactions
Under the same period, the volumes traded represented:
- 384,417 shares and €42,260,402.70 to the purchase
- 371,870 shares and €40,869,625.30 to the sell
Attachment
Half-year statement of IPSEN liquidity agreement – 2024 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
PARIS, FRANCE, July 8, 2024 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2024, the following resources were included to the dedicated liquidity account:
- 34,591 shares
- €1,418,034.45
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2024 and June 30, 2024 have been executed:
- 3,232 purchase transactions
- 2,431 sell transactions
Under the same period, the volumes traded represented:
- 384,417 shares and €42,260,402.70 to the purchase
- 371,870 shares and €40,869,625.30 to the sell
Attachment
Related Press Releases

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
